High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

Autor:	Keith D. Lindor, Kris V. Kowdley, Andrea A. Gossard, Denise M. Harnois, Jill C. Keach, Emmanouil Sinakos, Mohamad Imam, Alisha C. DeCook, Timothy M. McCashland, M. Edwyn Harrison, Velimir A. Luketic, Jan Petz, Roberta A. Jorgensen, Felicity Enders, Alex S. Befeler
Rok vydání:	2011
Předmět:	medicine.medical_specialty Cirrhosis Hepatology Bilirubin business.industry medicine.medical_treatment Gastroenterology Liver transplantation medicine.disease Placebo Ursodeoxycholic acid Primary sclerosing cholangitis Surgery chemistry.chemical_compound chemistry Internal medicine medicine Pharmacology (medical) Risk factor Adverse effect business medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 34:1185-1192
ISSN:	0269-2813
DOI:	10.1111/j.1365-2036.2011.04863.x
Popis:	Aliment Pharmacol Ther 2011; 34: 1185–1192 Summary Background Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To compare the risk of adverse clinical endpoints in patients with varying disease status. Methods We reviewed records from patients previously enrolled in a study evaluating the effects of high dose (28–30 mg/kg/day) UDCA in PSC. Patients were grouped according to treatment (UDCA vs. placebo) and baseline disease status (histological stage of PSC, total serum bilirubin). Development of clinical endpoints including death, liver transplantation, cirrhosis, oesophageal varices and cholangiocarcinoma was sought. Results A total of 150 patients were included of whom 49 patients developed endpoints. There was an increased development of endpoints among patients using UDCA vs. placebo (14 vs. 4, P = 0.0151) with early histological disease (stage 1–2, n = 88) but not with late stage (stage 3–4, n = 62) disease (17 vs. 14, P = 0.2031). Occurrence of clinical endpoints was also higher in patients receiving UDCA vs. placebo (16 vs. 2, P = 0.0008) with normal bilirubin levels (total bilirubin ≤1.0 mg/dL) but not in patients with elevated bilirubin levels (15 vs. 16, P = 0.6018). Among patients not reaching endpoints 31.7% had normalisation of their alkaline phosphatase levels when compared to 14.3% in patients who reached endpoints (P = 0.073). Conclusion The increased risk of adverse events with UDCA treatment when compared with placebo is only apparent in patients with early histological stage disease or normal total bilirubin.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d93168440f55042d88b7eb6f1758635a https://doi.org/10.1111/j.1365-2036.2011.04863.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.